Advancing Breakthroughs in Brain Health

Advancing CNS research with smarter clinical trials

pattern_standard
She felt like the weight of the trial was
on her shoulders. Then she found Rho.

The Neural Network Nexus:
Untangling the Complexity of CNS Trials

Every breakthrough starts with a question: How can we push science forward?

Neurological and psychiatric disorders don’t just affect individuals—they impact families, caregivers, and entire communities. Behind every study is a person searching for relief, for progress, for a future that looks different from today. At Rho, we don’t just run trials; we invest in the human stories behind them. We bring deep expertise in central nervous system (CNS) research and a commitment to smarter, more compassionate clinical trials that make a real difference.

why_rho_img

Why Rho?

Why Rho?

Experts who care
Our team has decades of experience in CNS trials, but more importantly, we never lose sight of the people at the heart of the research.
Thoughtful study design
We craft protocols that respect the complexities of neurological and psychiatric disorders and the patients who live with them.
Innovative data insights
We leverage biomarkers, imaging, and digital data capture to get to the answers faster and more effectively.
Patient-first approach
From recruitment to retention, we focus on building trials that work for people, not just data points.
Neurology and Psychiatry - SPOTLIGHT

Spotlight: Advancing Neurology and Psychiatry Research

In the past five years, we’ve supported more than 90 neurology and psychiatry studies across 840+ sites, including work in Parkinson’s, Alzheimer’s, MDD, ADHD, and substance use disorders. Our teams have guided programs from first-in-human to regulatory submission, including in rare and complex conditions.

These trials aren’t easy. We’ve helped launch more than 440 neurology sites and 400 psychiatry sites, enrolling over 6,500 participants—all while keeping timelines and expectations aligned.

But what matters most is the people behind those numbers. We collaborate closely with groups like the Michael J. Fox Foundation, Parkinson’s Foundation, and Davis Phinney Foundation to stay grounded in what matters most: research that’s not just scientifically sound, but truly centered on people.

Neurology and Psychiatry - SPOTLIGHT

Spotlight: Advancing Neurology and Psychiatry Research

In the past five years, we’ve supported more than 90 neurology and psychiatry studies across 840+ sites, including work in Parkinson’s, Alzheimer’s, MDD, ADHD, and substance use disorders. Our teams have guided programs from first-in-human to regulatory submission, including in rare and complex conditions.

These trials aren’t easy. We’ve helped launch more than 440 neurology sites and 400 psychiatry sites, enrolling over 6,500 participants—all while keeping timelines and expectations aligned.

But what matters most is the people behind those numbers. We collaborate closely with groups like the Michael J. Fox Foundation, Parkinson’s Foundation, and Davis Phinney Foundation to stay grounded in what matters most: research that’s not just scientifically sound, but truly centered on people.

Neurology and Psychiatry FAQ

What neurological and psychiatric disorders does Rho specialize in?

Rho has extensive experience in clinical trials for movement disorders, neurodegenerative diseases, psychiatric conditions, and rare CNS diseases. Our expertise spans Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, substance use disorders, and more.

Neurology and psychiatry trials often require specialized outcome measures, biomarker validation, and patient recruitment strategies for complex conditions. Rho’s deep expertise in CNS research helps sponsors navigate these complexities successfully.

Recruiting for neurological and psychiatric trials can be difficult due to strict inclusion criteria and long trial durations. Rho leverages targeted site selection, patient engagement strategies, and digital recruitment tools to enhance enrollment.

Yes. Our team has worked on numerous rare CNS disease trials, including those requiring innovative trial designs and regulatory pathways for orphan drug development.

Comprehensive support for neurology
and psychiatry trials

We provide full-service support for clinical trials across a wide range of CNS conditions:
Neurodegenerative diseases
Advancing research in Alzheimer’s, Parkinson’s, ALS, and related conditions.
Movement disorders
Expertise in dystonia, tremor, Huntington’s disease, and other motor dysfunctions.
Psychiatric and mood disorders
Shaping research strategies for trials in depression, schizophrenia, anxiety, substance use disorders, and PTSD.
Rare neurological conditions
Specialized experience in complex, low-prevalence disorders.
CNS biomarkers and imaging
Leveraging cutting-edge tools to enhance trial outcomes.

Ready to change lives together?
Behind every trial is a person waiting for progress. Let’s move science forward with purpose and heart.

Footer_CTA_Partner2
Scroll to Top
Andrew_Feigin-min

Andrew Feigin, MD

Dr. Feigin is Chief Medical Officer and a leading neurologist who brings 30 years of scientific excellence to Rho. A pioneer in clinical research, he’s led over 30 trials as site principal investigator and established renowned clinical trial programs for Parkinson’s, Huntington’s, Tourette syndrome, and other movement disorders. At Rho, he brings sharp insight and strategic savvy to the trials our team supports to maintain safety, integrity, and scientific rigor. Dr. Feigin is passionate about collaboration and innovation and sees Rho as the partner with the special combination of brainpower, quality, and teamwork to make an impact where it matters most.

Brett Gordon

With 20+ years of industry experience, Mr. Gordon has seen just about everything in clinical development. He can balance big-picture thinking with project level precision, which he combines with his knack for building strong relationships. Mr. Gordon has managed trials from first-in-man, single-center Phase 1 trials to sprawling 100+ site Phase 3 trials, both domestic and global. While he has background in CNS and pain trials, ADHD is where he has really left his mark, providing oversight of trial programs for at least 5 compounds. Mr. Gordon understands that clinical research can get complicated—but he makes it feel doable.

Peter Schmidt, Ph.D.

Dr. Schmidt is President and Chief Scientific Officer and provides strategic and scientific leadership across the organization. A neuroscientist by training with degrees from Harvard and Cornell, he has been a catalyst in many contexts: inventor, principal investigator, statistician, and leader. With decades of experience in biomedical research—from Parkinson’s disease to cystic fibrosis to Huntington’s—he brings the insight and expertise to further strengthen Rho’s reputation as a trusted research partner with the know-how to solve complex problems. While Dr. Schimdt maintains that clinical research is a serious business, he believes working with your CRO shouldn’t feel like it.